Astrazeneca PLC’s (AZN) “Buy” Rating Reiterated at Deutsche Bank AG
Astrazeneca PLC (NYSE:AZN)‘s stock had its “buy” rating reissued by Deutsche Bank AG in a research report issued to clients and investors on Monday.
AZN has been the topic of a number of other research reports. Citigroup Inc. restated a “buy” rating on shares of Astrazeneca PLC in a research note on Wednesday, July 27th. Bank of America Corp. set a $41.40 target price on Astrazeneca PLC and gave the company a “buy” rating in a research note on Thursday, September 8th. Piper Jaffray Cos. began coverage on Astrazeneca PLC in a research note on Friday, September 23rd. They issued an “overweight” rating on the stock. TheStreet upgraded Astrazeneca PLC from a “hold” rating to a “buy” rating in a research note on Friday, July 22nd. Finally, BNP Paribas cut Astrazeneca PLC from an “outperform” rating to a “neutral” rating in a research report on Tuesday, September 13th. Three research analysts have rated the stock with a sell rating, eight have given a hold rating, eleven have given a buy rating and two have assigned a strong buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $37.56.
Shares of Astrazeneca PLC (NYSE:AZN) traded down 0.71% on Monday, hitting $32.06. The stock had a trading volume of 3,693,999 shares. Astrazeneca PLC has a 1-year low of $26.97 and a 1-year high of $35.04. The stock has a market cap of $81.11 billion, a P/E ratio of 36.64 and a beta of 0.75. The firm’s 50-day moving average is $33.23 and its 200 day moving average is $30.79.
This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at https://www.americanbankingnews.com/2016/10/10/astrazeneca-plcs-azn-buy-rating-reiterated-at-deutsche-bank-ag.html
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, beating analysts’ consensus estimates of $0.76 by $0.07. Astrazeneca PLC had a return on equity of 28.02% and a net margin of 9.23%. The firm had revenue of $5.60 billion for the quarter, compared to the consensus estimate of $5.56 billion. During the same quarter in the previous year, the company posted $1.21 earnings per share. The business’s quarterly revenue was down 4.0% compared to the same quarter last year. Equities analysts forecast that Astrazeneca PLC will post $2.97 EPS for the current year.
The company also recently declared a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were issued a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s dividend payout ratio (DPR) is 78.29%.
Institutional investors have recently bought and sold shares of the stock. Dodge & Cox boosted its position in Astrazeneca PLC by 24.9% in the second quarter. Dodge & Cox now owns 32,532,723 shares of the company’s stock valued at $982,163,000 after buying an additional 6,483,073 shares during the period. Capital International Investors boosted its position in Astrazeneca PLC by 22.1% in the second quarter. Capital International Investors now owns 20,473,479 shares of the company’s stock valued at $618,094,000 after buying an additional 3,705,199 shares during the period. Primecap Management Co. CA boosted its position in Astrazeneca PLC by 17.4% in the second quarter. Primecap Management Co. CA now owns 15,365,950 shares of the company’s stock valued at $463,898,000 after buying an additional 2,281,675 shares during the period. BlackRock Investment Management LLC boosted its position in Astrazeneca PLC by 73.2% in the second quarter. BlackRock Investment Management LLC now owns 7,207,036 shares of the company’s stock valued at $217,580,000 after buying an additional 3,046,268 shares during the period. Finally, Renaissance Technologies LLC boosted its position in Astrazeneca PLC by 14.6% in the first quarter. Renaissance Technologies LLC now owns 5,682,800 shares of the company’s stock valued at $160,028,000 after buying an additional 723,100 shares during the period. 11.39% of the stock is owned by hedge funds and other institutional investors.
About Astrazeneca PLC
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.